Effect to Secon- Generation Sulfony lures on Survival in Patients With Diabetes Mekllitus After Myocarial Infarction

Arruda-Olson, Adelaide M.; Patch III, Richard K.; Leibson, Cynthia L.; Vella, Adrian; Frye, Robert L.; Weston, Susan A.; Killian, Jill M.; Roger, Veronique L.
January 2009
Mayo Clinic Proceedings;Jan2009, Vol. 84 Issue 1, p28
Academic Journal
OBJECTIVE: To examine possible adverse effects of sulfonylureas on survival among patients with diabetes mellitus (DM) who experience a myocardial infarction (MI). PATIENTS AND METHODS: Residents of Olmsted County, Minnesota, with an MI that met standardized criteria from January 1, 1985, through December 31, 2002, were followed up for mortality. RESULTS: Among 2189 patients with MI (mean ± SD age, 68±14 years; 1237 men [57%]), 409 (19%) had DM. The 23 patients treated with first-generation sulfonylureas, biguanides, or thiazolidinediones were excluded from analyses. Among the remaining 386 patients with DM, 120 (31%) were taking second- generation sulfonylureas, 180 (47%) were taking insulin, and 86 (22%) were receiving nonpharmacological treatment. Patients with DM treated with second-generation sulfonylureas were more likely to be men and have higher creatinine clearance than those treated with Insulin. After adjusting for age, sex, Killip class, duration of DM, creatinine clearance, and reperfusion therapy or revascularization, patients treated with second-generation sulfonylureas had a lower risk of death than did diabetic patients receiving Insulin (hazard ratio, 0.41; 95% confidence Interval, 0.21-0.80; P=.009). CONCLUSION: These population-based data do not support the concern about an adverse effect of second-generation sulfonylureas on survival after MI and underscore the importance of population-based studies of surveillance of drug safety.


Related Articles

  • Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease. JIE HONG; YIFEI ZHANG; SHENGHAN LAI; ANKANG LV; QING SU; YAN DONG; ZHIGUANG ZHOU; WEILI TANG; JIAJUN ZHAO; LIANQUN CUI; DAJIN ZOU; DAWANG WANG; HONG LI; CHAO LIU; GUOTING WU; JIE SHEN; DALONG ZHU; WEIQING WANG; WEIFENG SHEN; GUANG NING // Diabetes Care;May2013, Vol. 36 Issue 5, p1304 

    OBJECTIVE--The two major classes of antidiabetic drugs, sulfonylureas and metformin, may differentially affect macrovascular complications and mortality in diabetic patients. We compared the long-term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic...

  • New Study on Thiazolidinediones May Show Benefits. Elliott, William T. // Clinical Oncology Alert;Jun2008, Vol. 24 Issue 6, p1 

    The article discusses the results of a study which compares pioglitazone with sulfonylurea glimepiride measuring the progression of coronary atherosclerosis in patients with type 2 diabetes. Based on the study, glimepiride increased percent change in atheroma volume (PAV) by 0.73% while...

  • Anti-Diabetes Drug Utilization in Diabetic Patients with Coronary Heart Disease (CHD) Enrolled in BARI 2D Trial. Mooradian, Arshag D.; Albert, Stewart G.; Lombardero, Manuel; Brooks, Maria Mori // Diabetes;Jun2007 Supplement 1, Vol. 56, pA549 

    Although anti-diabetes drug therapy should be individualized, there are enough scientific data to support general principles in drug selection. To examine the current treatment of diabetes in a high risk population, the anti-diabetic drug use was analyzed in the participants of BARI 2D, a...

  • The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Pantalone, Kevin; Kattan, Michael; Yu, Changhong; Wells, Brian; Arrigain, Susana; Jain, Anil; Atreja, Ashish; Zimmerman, Robert // Acta Diabetologica;Jun2009, Vol. 46 Issue 2, p145 

    Oral anti-diabetic agents have been associated with adverse cardiovascular events in type 2 diabetes (DM2). We investigated the risk of coronary artery disease (CAD), congestive heart failure (CHF), and mortality using multivariable Cox models in a retrospective cohort of 20,450 DM2 patients...

  • Risk of CV disorders with insulin or sulfonylureas.  // Reactions Weekly;10/4/2008, Issue 1222, p3 

    The article reports on the results of a study on the association between serious ischemic cardiac outcomes and medications used to treat diabetes. Results showed that the use of insulin or sulfonylureas appeared to be linked with an increased risk of ischaemic cardiovascular disorders in...

  • tolbutamide.  // Royal Society of Medicine: Medicines;2002, p539 

    This article provides information on tolbutamide, a sulphonylurea which is used for the treatment of Type II diabetes. Administration of the drug is oral. It may be chosen for patients with renal impairment and in the elderly because it is shorter-acting.

  • The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. McAlister, Finlay A.; Eurich, Dean T.; Majumdar, Sumit R.; Johnson, Jeffrey A. // European Journal of Heart Failure;Jul2008, Vol. 10 Issue 7, p703 

    Abstract: Aim: To determine if the risk of developing heart failure (HF) is associated with the use of sulfonylurea or metformin in patients with diabetes. Methods: Retrospective cohort study of all adults without HF newly treated with oral antidiabetic drugs in Saskatchewan, Canada between 1991...

  • Impact of Oral Antihyperglycemic Therapy on All-Cause Mortality Among Patients With Diabetes in the Veterans Health Administration. Kahler, Kristijan H.; Rajan, Mangala; Rhoads, George G.; Safford, Monika M.; Demissie, Kitaw; Lu, Shou-En; Pogach, Leonard M. // Diabetes Care;Jul2007, Vol. 30 Issue 7, p1689 

    OBJECTIVE -- The objective of this analysis was to evaluate the impact of several classes of oral antihyperglycemic therapy relative to sulfonylurea monotherapy on all-cause mortality among a cohort of patients with diabetes from the Veterans Health Administration (VHA). RESEARCH DESIGN AND...

  • Rosiglitazone patients mostly switched to new agents.  // PharmacoEconomics & Outcomes News;12/15/2007, Issue 543, p10 

    The article provides information on a study on diabetics receiving rosiglitazone conducted by TNS Healthcare's "DiabetesDynamics USA." The study revealed that between July and September 2007, over half of all patients have taken off rosiglitazone because of reported cardiac risk. The patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics